ArticleThe American journal of pathology2025
Enhancement of Tumor Necrosis Factor-α-Mediated Hepatic Apoptosis and Liver Injury by Hepatitis B Virus Surface Antigen.
Article in The American journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor necrosis factor-α (TNF-α) is a highly pleiotropic cytokine with a variety of biological functions, such as cell proliferation, metabolic activation, inflammatory response, and cell death. TNF-α can induce a variety of mechanisms to initiate hepatocyte apoptosis, resulting in subsequent liver damage. Hepatitis B virus surface antigen (HBsAg) is the most abundant hepatitis B virus protein in the hepatocyte during chronic virus infection. However, its role in TNF-α-mediated apoptosis of hepatocytes has not been revealed. We report here that HBsAg promotes TNF-α-mediated hepatocyte apoptosis through inhibiting TNF-α-mediated anti-apoptotic complex I-dependent NF-κB activation and enhancing TNF-α-mediated pro-apoptotic complex II assembly. Mechanistically, HBsAg-mediated inhibition of complex I assembly was associated with down-regulation of K63-linked receptor-interacting protein kinase 1 (RIPK1) ubiquitination through repression of cellular inhibitor of apoptosis protein-1 (cIAP1) expression. Secretion-deficient HBsAg variant S204R enhances their pro-apoptotic abilities via further inhibition of RIPK1 ubiquitination. Expression of HBsAg in mice injected with recombinant adenovirus-associated virus 8 promoted D-galactosamine/lipopolysaccharide-induced TNF-α-mediated liver injury and damage by a mouse model. In conclusion, HBsAg may predispose hepatocytes to TNF-α-mediated apoptosis and mice to acute liver injury by switching TNF-α-mediated anti-apoptotic complex I to pro-apoptotic complex II, showing novel insights into the underlying mechanisms of hepatitis B virus-associated liver injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.